Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Monica McGill

Psychiatry Goldsboro, NC Medical Doctor

NPI 1477711067 CMS profile 1258727

2719 Graves Dr, Suite 5, Goldsboro, NC 27534

Open in the dashboard

General payments

$3,622

307 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monica McGill of Goldsboro, NC is reported in the CMS Open Payments database as having received $3,622 across 307 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $414 20
2024 General $190 10
2023 General $705 61
2022 General $731 63
2021 General $706 63
2020 General $449 44
2019 General $428 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monica McGill
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Monica McGill were reported at $414. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Monica McGill Psychiatry median Middle half National median
2019 $428 $184 $59–$605 $163
2020 $449 $119 $36–$372 $114
2021 $706 $143 $43–$576 $132
2022 $731 $153 $50–$590 $149
2023 $705 $170 $56–$651 $160
2024 $190 $179 $57–$673 $164
2025 $414 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,183 131 payments
  2. Otsuka America Pharmaceutical, Inc. $509 28 payments
  3. ITI, Inc. $357 19 payments
  4. Allergan Inc. $325 50 payments
  5. Alkermes, Inc. $238 15 payments
  6. Lundbeck LLC $201 12 payments
  7. Janssen Pharmaceuticals, Inc $136 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $135 7 payments
  9. Neurocrine Biosciences, Inc. $110 6 payments
  10. Teva Pharmaceuticals USA, Inc. $98 7 payments
  11. Other $330 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,619 306 payments
  2. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $960 120 payments
  2. VRAYLAR Neuroscience $543 60 payments
  3. CAPLYTA $357 19 payments
  4. REXULTI Psychiatry $344 18 payments
  5. ABILIFY MAINTENA $269 16 payments
  6. ARISTADA Cns $208 13 payments
  7. ARISTADA Cns $208 13 payments
  8. LYBALVI $165 10 payments
  9. ARISTADA INITIO $145 9 payments
  10. REXULTI Psychiatry $137 8 payments
  11. Other $1,395 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

322

Median for Psychiatry & Neurology: 100

Drug cost

$68,831

Median for Psychiatry & Neurology: $2,986

Branded share of claims

17.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 17 $33,756
Vraylar Cariprazine Hcl Brand 13 $18,582
Lurasidone Hcl Generic 16 $10,898
Hydroxyzine Hcl Generic 32 $1,052
Duloxetine Hcl Generic 28 $813
Aripiprazole Generic 24 $590
Buspirone Hcl Generic 31 $558
Bupropion Xl Bupropion Hcl Brand 16 $534
Mirtazapine Generic 32 $524
Quetiapine Fumarate Er Quetiapine Fumarate Brand 11 $466

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $77
$77 13 —
REXULTI
  • Lundbeck LLC $36
  • Otsuka America Pharmaceutical, Inc. $25
$61 — —
CAPLYTA
  • ITI, Inc. $18
$18 17 —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $18
$18 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

307 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record